Drug Combination Details

General Information of the Combination (ID: C02533)
Name Bufalin   NP Info  + Gemcitabine   Drug Info 
Structure +
Disease
Pancreatic cancer [ICD-11: 2C10]
Phase 2 [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    Molecule(s)
                    Regulation		 Up-regulation Expression MAP3K5  Molecule Info 
Pathway MAP
                    In-vitro Model BxPC-3 CVCL_0186 Pancreatic ductal adenocarcinoma Homo sapiens
MIA PaCa-2 CVCL_0428 Pancreatic ductal adenocarcinoma Homo sapiens
PANC-1 CVCL_0480 Pancreatic ductal adenocarcinoma Homo sapiens
                    In-vivo Model To establish xenograft model, each mouse was subcutaneously injected with 6x106 Mia PaCa-2 cells in the back.
                    Experimental
                    Result(s)		 Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer.
References
Reference 1 ClinicalTrials.gov (NCT00837239) Huachansu and Gemcitabine in Pancreatic Cancer.
Reference 2 Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Oncol Lett. 2012 Oct;4(4):792-798.
 Download Picture         KEGG Link